# Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

> **NCT04716686** · PHASE2 · RECRUITING · sponsor: **Shandong University** · enrollment: 83 (estimated)

## Conditions studied

- Endometrial Carcinoma
- Serous Carcinoma

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04716686
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04716686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04716686, "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04716686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*